CDC25B and neoplasm: We used two models and three pancreatic cancer cell lines with contrasting levels of CDC25B to compare the efficacy of the BET inhibitor JQ1, which inhibits the expression of CDC25B, or of gemcitabine, a standard of care for this tumor type.